ES2176785T3 - Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz. - Google Patents

Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz.

Info

Publication number
ES2176785T3
ES2176785T3 ES97943017T ES97943017T ES2176785T3 ES 2176785 T3 ES2176785 T3 ES 2176785T3 ES 97943017 T ES97943017 T ES 97943017T ES 97943017 T ES97943017 T ES 97943017T ES 2176785 T3 ES2176785 T3 ES 2176785T3
Authority
ES
Spain
Prior art keywords
active principle
pharmaceutical composition
modified release
procedure
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97943017T
Other languages
English (en)
Inventor
Nabil Farah
Philippe Barthelemy
Joseph Joachim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gattefosse Holding
Original Assignee
Gattefosse Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gattefosse Holding filed Critical Gattefosse Holding
Application granted granted Critical
Publication of ES2176785T3 publication Critical patent/ES2176785T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO DE FABRICACION DE UNA COMPOSICION FARMACEUTICA CON LIBERACION MODIFICADA DE PRINCIPIO ACTIVO, QUE COMPRENDE UN PRINCIPIO ACTIVO, UN AGENTE MATRICIAL LIPIDICO Y UN ADITIVO CARACTERIZADO PORQUE: A LA VEZ QUE SE CALIENTE Y SE FLUIDIFICA, SE MEZCLA UN POLVO DE UN COMPONENTE SELECCIONADO ENTRE EL GRUPO QUE COMPRENDE EL PRINCIPIO ACTIVO Y EL ADITIVO; SEPARADAMENTE, SE LICUA, EN CALIENTE, DICHO AGENTE MATRICIAL LIPIDICO Y SE REVISTE DICHO POLVO, POR PULVERIZACION DE DICHO AGENTE MATRICIAL LIPIDICO SOBRE LOS GRANOS INDIVIDUALIZADOS Y POR ULTIMO SE REDUCE LA TEMPERATURA PARA PERMITIR LA SOLIDIFICACION DEL AGENTE MATRICIAL LIPIDICO.
ES97943017T 1996-10-01 1997-09-29 Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz. Expired - Lifetime ES2176785T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612156A FR2753904B1 (fr) 1996-10-01 1996-10-01 Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication

Publications (1)

Publication Number Publication Date
ES2176785T3 true ES2176785T3 (es) 2002-12-01

Family

ID=9496393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97943017T Expired - Lifetime ES2176785T3 (es) 1996-10-01 1997-09-29 Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz.

Country Status (9)

Country Link
US (1) US6194005B1 (es)
EP (1) EP0935459B1 (es)
JP (1) JP2001501218A (es)
KR (1) KR20000048761A (es)
AU (1) AU4464897A (es)
DE (1) DE69713367T2 (es)
ES (1) ES2176785T3 (es)
FR (1) FR2753904B1 (es)
WO (1) WO1998014176A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
FR2784895B1 (fr) * 1998-10-23 2004-12-17 Gattefosse Ets Sa Comprime a croquer a gout masque et liberation immediate du principe actif et procede de fabrication
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
FR2822381B1 (fr) * 2001-03-20 2004-10-22 Bio Obtention Sc Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse
SK286107B6 (sk) * 2002-04-12 2008-03-05 Zentiva, A. S. Analgeticky účinný perorálny liečivý prípravok s kontrolovaným uvoľňovaním opioidnej účinnej látky a spôsob jeho prípravy
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US20030235613A1 (en) * 2002-06-19 2003-12-25 Cts Chemical Industries Ltd. Popping oral administration form
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
US7364755B2 (en) * 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
DE102007026550A1 (de) 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
US20090004285A1 (en) * 2007-06-29 2009-01-01 Liangping Yu Stable non-disintegrating dosage forms and method of making same
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
US11071805B2 (en) 2013-04-22 2021-07-27 Sealantium Medical Ltd. Fibrinogen-based tissue adhesive patches
JP6816135B2 (ja) 2015-10-19 2021-01-20 シーレーンチウム メディカル リミテッド フィブリノーゲンに基づく改善された組織接着剤パッチ
US11471556B2 (en) 2015-10-19 2022-10-18 Sealantium Medical Ltd. Fibrinogen-based tissue adhesive patch
US20180207328A1 (en) * 2017-01-22 2018-07-26 Kamalesh K. Rao Implantable Compositions for Pain Management
JP2021509111A (ja) 2017-12-27 2021-03-18 グラール ソシエタ ア レスポンサビリタ リミタータ 遅延放出固体配合物の調製のための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4129666A (en) * 1977-04-29 1978-12-12 Walter Wizerkaniuk Method of providing pellets with a water insoluble coating using a melt
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
JP2553258B2 (ja) * 1991-05-20 1996-11-13 三菱化学株式会社 ワックス被覆製剤の製造方法
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
ES2199981T3 (es) * 1994-02-16 2004-03-01 Abbott Laboratories Modo de preparacion de formulaciones farmaceuticas de particulas finas.

Also Published As

Publication number Publication date
WO1998014176A1 (fr) 1998-04-09
EP0935459A1 (fr) 1999-08-18
FR2753904A1 (fr) 1998-04-03
AU4464897A (en) 1998-04-24
FR2753904B1 (fr) 1998-10-30
EP0935459B1 (fr) 2002-06-12
DE69713367T2 (de) 2003-03-06
DE69713367D1 (de) 2002-07-18
KR20000048761A (ko) 2000-07-25
JP2001501218A (ja) 2001-01-30
US6194005B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
ES2176785T3 (es) Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz.
GT199900203A (es) Composiciones de celecoxib.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
AR053292A1 (es) Un sistema de suministro para dos o mas componentes acivos como parte de una composicion comestible
ES2187822T3 (es) Comprimidos de disgregacion rapida.
ES2422655T3 (es) Formulaciones de liberación inmediata potenciadas de topiramato
ES2129048T3 (es) Composicion estabilizada de hormona paratiroide.
GT200000108A (es) Procedimiento para la obtencion de composiciones antibacteriales.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
MX173203B (es) , "composiciones cosmeticas despigmentantes a base de acido cafeico
BR112016002915A2 (pt) formulação agroquímica pulverizável, formulação concentrada, uso de um éster graxo de um poliol c3 a c8, ou oligômero do mesmo, e, métodos para reduzir o desvio de pulverização e para tratamento de vegetação para controlar pestes e/ou fornecer nutrientes
PE20001477A1 (es) Articulo absorbente que tiene una composicion estable para el cuidado de la piel
BRPI0516718A (pt) forma de dosagem de ibuprofeno de liberação modificada
GT200500349A (es) Formulaciones de benzoxazoles substituidos
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
CO5031299A1 (es) Composiciones antitranspirantes
ES2152367T3 (es) Composiciones fertilizantes en emulsion agua en aceite.
BRPI0408555A (pt) sistema de liberação controlada
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
AR026240A1 (es) Empleo de polisiloxanos con grupos de amonio cuaterinario como agentes auxiliares de formulacion y composiciones que les contienen
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais